Upstream Bio (UPB) Other Non-Current Liabilities (2023)

Upstream Bio (UPB) recorded quarterly Other Non-Current Liabilities of $2.9 million in Q4 2023.

Upstream Bio (UPB) Other Non-Current Liabilities (2023) Analysis & Trends

Upstream Bio's Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $2.9 million for Q4 2023.

In Q4 2023, Other Non-Current Liabilities changed N/A year-over-year to $2.9 million; the TTM figure through Dec 2023 stood at $2.9 million (changed N/A YoY), while the FY2023 annual figure was $2.9 million, changed N/A from the prior year.
Other Non-Current Liabilities was $2.9 million for Q4 2023 at Upstream Bio.
In the past five years, Other Non-Current Liabilities ranged from a high of $2.9 million in Q4 2023 to a low of $2.9 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Upstream Bio	339.03 Mn	339.03 Mn	-3.94 Mn

Download Data

Date	Value
Dec 31, 2023	2.87 Mn